# Cadonilimab Plus Chemotherapy as First-line Treatment for PD-L1 Negative NSCLC

> **NCT06424821** · PHASE2 · RECRUITING · sponsor: **Shanghai Pulmonary Hospital, Shanghai, China** · enrollment: 54 (estimated)

## Conditions studied

- NSCLC

## Interventions

- **DRUG:** Cadonilimab

## Key facts

- **NCT ID:** NCT06424821
- **Lead sponsor:** Shanghai Pulmonary Hospital, Shanghai, China
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-07-04
- **Primary completion:** 2024-09-04
- **Final completion:** 2025-09-04
- **Target enrollment:** 54 (ESTIMATED)
- **Last updated:** 2024-05-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06424821

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06424821, "Cadonilimab Plus Chemotherapy as First-line Treatment for PD-L1 Negative NSCLC". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06424821. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*